Pharmaceutical Technology

FEBRUARY 23, 2023

Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 111

Medicine In-Vivo In-Vitro Development 111

pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Zinc fingers. billion in funding.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Drug Discovery World

APRIL 8, 2024

Outstanding Achievement Award Pfizer Chairman and CEO Dr Albert Bourla received the 2024 AACR Outstanding Achievement Award for Service to Cancer Science and Medicine on behalf of Pfizer during the Opening Ceremony.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

APRIL 5, 2023

The CBC is the discovery engine of the National Cancer Institute (NCI) Experimental Therapeutics (NExT) Program, administered through the Frederick National Laboratory for Cancer Research (FNLCR), a federal national laboratory sponsored by the NCI, part of the National Institutes of Health, and currently operated by Leidos Biomedical Research.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

pharmaphorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells.

In-Vivo 105

In-Vivo Engineer Scientist Life Science 105

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

Scienmag

FEBRUARY 10, 2021

Credit: Lei Dong, Nanjing University Scientists from Nanjing University and the University of Macau have devised a new approach to extend the survival of transplanted probiotics in vivo, enhancing the efficacy of cancer chemo-/immunotherapies in mice.

In-Vivo 69

In-Vivo Scientist Engineer Medicine 69

Drug Discovery World

SEPTEMBER 14, 2023

Excluding contributions from Comirnaty and Paxlovid, company revenues grew $537 million, or 5%, operationally. AstraZeneca saw total revenue reach $22,295m, up 4% despite a decline of $2,181m from Covid-19 medicines. Excluding Covid-19 medicines, total revenue increased 16% and product sales increased 15%. Specialty care grew 11.8%

Drugs 59

Drugs Vaccination Vaccine Medicine 59

Pharmaceutical Technology

MAY 17, 2023

Scribe Therapeutics has entered a strategic collaboration with Eli Lilly and Company subsidiary Prevail Therapeutics for accelerating in vivo CRISPR-based therapies to target the causes of serious neurological and neuromuscular diseases. Scribe will receive $75m, including an upfront payment and equity investment via a convertible note.

Genetics 130

Genetics Medicine In-Vivo Gene Therapy 130

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). Within the past year, the sector saw the EU’s landmark approval of the first allogeneic T cell therapy as well as the approval of several new gene therapies in the US. billion in 2020 to $15.5

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

Drug Discovery World

JUNE 30, 2023

Research tools, safety testing and regenerative medicines – these endless stem cell applications are powering precision, speed, and new modalities in drug development. Stem cells for use in drug discovery Stem cells are fast becoming an invaluable tool in the drug discovery process. This article is sponsored by Charles River.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

JULY 22, 2022

In vivo models, particularly HIS models, allow preliminary investigation of cell-based therapeutic strategies—often in combination with other therapeutic modalities—to overcome the limitations and challenges of T cell-based immuno-oncology treatments and identify effective options for clinical investigation. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

OCTOBER 21, 2022

Ibrahim Ozbolat, Professor of Engineering Science and Mechanics, Biomedical Engineering and Neurosurgery, Penn State, explained how their work will impact cancer research: “We’ve developed a tool that serves as a clinical test platform to safety and accurately evaluate experimental therapies. 3D bioprinted breast cancer tumours.

In-Vivo 52

In-Vivo Research Drugs Engineer 52

Delveinsight

FEBRUARY 25, 2021

Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Cambridge, Massachusetts-based Beam aims to make more precise edits with genetic medicines, which employ base-editing.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

OCTOBER 8, 2020

Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Oakes. At the moment, most CRISPR-based medicines rely on the modification of cells outside the body, that are then used as therapies. Benjamin Oakes.

Gene Editing 69

Gene Editing Gene In-Vivo Clinical Trials 69

Roots Analysis

DECEMBER 8, 2021

Biopreservation is the exclusive biological approach designated for the preservation of cells, tissues and organs ex-vivo for the purpose of storage, shipment and transportation. Biopreservation media is one of the most crucial entity in conferring effectiveness. F) to 8°C (46.4°F).

Packaging 52

Packaging Packaging In-Vivo Biobanking 52

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. A Meeting Point for the Field’s Experts. About Hanson Wade.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

The Pharma Data

NOVEMBER 5, 2020

Before embarking on his professional journey, in 1961, Dr. Van Kampen earned a Bachelor degree in Veterinary Science from Utah State University, in 1964, a Doctorate of Veterinary Medicine from Colorado State University, and in 1967, a Doctorate of Philosophy in Comparative Pathology from the University of California at Davis in 1967.

Research 52

Research Vaccination Vaccine Doctors 52

Drug Discovery World

JUNE 7, 2023

DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs).

In-Vivo 52

In-Vivo Gene Editing Engineer Bioinformatics 52

The Pharma Data

JUNE 17, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). A modified version of the Cv2.1169 antibody was also effective at treating SARS-CoV-2 infection in mice and hamsters.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

The Pharma Data

DECEMBER 9, 2020

The new company, created by Hillhouse Capital Venture Partners, launched this week with a mission to pursue the most promising advances in medicine for underserved patients in Asia and around the world. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JANUARY 12, 2021

We look forward to bringing these same insights in immuno-oncology to Takeda to advance together potentially valuable new medicines for patients with cancer.”. KSQ’s proprietary CRISPRomics® discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. sales for that product.

Development 52

Development Research In-Vivo Genome 52

Drug Discovery World

JULY 5, 2023

For example, in CAR-T-cell therapy, scientists can take T-cells from a patient and ex vivo (outside the body) genetically engineer them to effectively target and kill cancerous cells, then infuse them back in to the patient. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?

Research 98

Research Protein Scientist Immune Response 98

Drug Discovery World

NOVEMBER 16, 2022

Therefore, while researchers can understand just how a drug molecule impacts a cell, they can’t be sure that it will perform the same when used in-vivo. . One of these benefits is how cells grown in this type of culture are able to interact with their surroundings, similar to how they would perform in-vivo. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

SEPTEMBER 6, 2022

This area of medicine, which turns our own bodies into agents of combat to fight disease, has quickly become one of the most promising fields in treating deadly diseases such as cancer, central nervous system disorders and even musculoskeletal conditions. . billion, compared to $19.9 million price point per dose. Cancer is king .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

APRIL 3, 2023

Optimer binders are engineered to overcome these problems. From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. To what do you attribute your success?

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

APRIL 25, 2023

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

XTalks

AUGUST 5, 2020

Single cell sequencing has revolutionized the study of biological tissues and systems at the cellular and molecular level. Recent advances in the technology have allowed for the interrogation of distinct subsets of cell populations within tissues, and associated molecular markers that may function as important disease drivers.

Gene Expression 112

Gene Expression Development RNA Drugs 112

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. However, not all innovations are equal and nor do they follow a constant upward trend.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

The Pharma Data

DECEMBER 10, 2020

ImmunityBio has engineered the vector to overcome this problem and has shown that its second-generation adenovirus vector can safely and effectively deliver its cargo even in patients with pre-existing adenovirus immunity. This blocking of viral replication was observed in both the lung and nasal passages.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

DECEMBER 20, 2023

As we step into 2024, the life sciences continue to evolve at an unprecedented pace, driven by technological innovation, a deeper understanding of human biology and the application of new technologies in areas like drug development and health wearables. Regulatory bodies are also taking note of the applications of AI in drug development.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

Drug Discovery World

JANUARY 23, 2023

Demonstrating benefits such as fewer side effects and lower cost to enhanced efficacy and accessibility, this emerging therapeutic modality is giving hope to patients and clinicians. The momentum of RNA technologies is apparent in the significant increase in scientific knowledge, IP and deal-making value over recent years.

RNA 98

RNA Genome Genomics Engineer 98